For the quarter ending 2025-09-30, KROS made $14,262K in revenue. -$7,280K in net income. Net profit margin of -51.04%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 14,262 | 18,168 | 211,246 | 388 |
| Research and development | 19,519 | 43,503 | 48,709 | 49,225 |
| General and administrative | 10,127 | 14,482 | 10,497 | 9,820 |
| Total operating expenses | 29,646 | 57,985 | 59,206 | 59,045 |
| Income (loss) from operations | -15,384 | -39,817 | 152,040 | -58,657 |
| Dividend income | 6,933 | 7,120 | 6,792 | 5,793 |
| Other expense, net | -253 | -221 | -338 | -92 |
| Total other income, net | 6,680 | 6,899 | 6,454 | 5,701 |
| Income (loss) before income taxes | -8,704 | -32,918 | 158,494 | - |
| Income tax (provision) benefit | -1,424 | -2,222 | 10,043 | - |
| Net income (loss) | -7,280 | -30,696 | 148,451 | -52,956 |
| Net income (loss) per share of common stock - basic (in usd per share) | -0.18 | -0.76 | 3.66 | -1.41 |
| Net income (loss) per share of common stock - diluted (in usd per share) | -0.18 | -0.76 | 3.62 | -1.41 |
| Weighted average shares of common stock outstanding - basic (in shares) | 40,623,364 | 40,612,907 | 40,559,355 | 37,590,727 |
| Weighted average shares of common stock outstanding - diluted (in shares) | 40,623,364 | 40,612,907 | 41,021,325 | 37,590,727 |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)